ondansetron has been researched along with Myelodysplastic Syndromes in 1 studies
Ondansetron: A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.
Myelodysplastic Syndromes: Clonal hematopoietic stem cell disorders characterized by dysplasia in one or more hematopoietic cell lineages. They predominantly affect patients over 60, are considered preleukemic conditions, and have high probability of transformation into ACUTE MYELOID LEUKEMIA.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lacerda, JF | 1 |
| Martins, C | 1 |
| Carmo, JA | 1 |
| Lourenço, MF | 1 |
| Araújo Pereira, ME | 1 |
| Rodrigues, A | 1 |
| Juncal, C | 1 |
| Lacerda, JM | 1 |
1 trial available for ondansetron and Myelodysplastic Syndromes
| Article | Year |
|---|---|
Randomized trial of ondansetron, granisetron, and tropisetron in the prevention of acute nausea and vomiting.
Topics: Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Femal | 2000 |